ARTICLE | Company News
Atlas' build-to-buy Arteaus sells Emgality royalties for $260M
April 5, 2019 5:11 PM UTC
Arteaus sold its royalty rights for Lilly's Emgality galcanezumab-gnlm to Royalty Pharma (New York, N.Y.) for $260 million.
Atlas Ventures and OrbiMed Advisors launched Arteaus Therapeutics LLC in October 2011 with $18 million to develop Emgality through Phase II testing, after which Eli Lilly and Co. (NYSE:LLY) exercised its option to reacquire the drug...
BCIQ Target Profiles